Breaking the Benzodiazepine Cycle: Why Long-Term Use Isn’t the Answer to Anxiety

It never ceases to astonish me when I encounter a young patient who has been prescribed 2 mg of alprazolam daily for years under the guise of treating an “anxiety disorder.” The situation becomes even more concerning when they’re simultaneously taking 30 mg of Adderall. Discussing the risks of long-term benzodiazepine use or proposing an evidence-based tapering plan over 6–12 months often elicits a defensive or negative reaction. However, I make it a point to emphasize that my approach is rooted in evidence and science, which do not support the long-term use of benzodiazepines for anxiety disorders. As clinicians, we have a responsibility to address this widespread prescribing practice, educate patients about the associated risks, and prioritize safer, evidence-based treatments.

RCT Evidence

1. Duration of Trials:
   • Most RCTs investigating BZDs in anxiety disorders are short-term, typically lasting 4–12 weeks. Very few extend beyond 6 months, leading to a scarcity of long-term controlled data.
2. Efficacy:
   • BZDs, such as diazepam, alprazolam, and clonazepam, are effective in the short term for managing anxiety symptoms in generalized anxiety disorder (GAD), panic disorder (PD), and social anxiety disorder (SAD).
   • Studies often show comparable short-term efficacy between BZDs and SSRIs or SNRIs, though BZDs act faster.
3. Tapering and Relapse:
   • Long-term RCTs involving tapering strategies suggest that discontinuation often leads to relapse of anxiety symptoms, which can complicate the interpretation of their role in maintaining anxiety control versus masking symptoms.
   • Some studies (e.g., long-term diazepam use in GAD) found sustained symptom relief in individuals maintained on the medication compared to those tapered off, but these are limited and subject to biases such as withdrawal effects.
4. Combination with Other Treatments:
   • Some RCTs have explored BZDs as adjunctive therapy, particularly during the initiation of antidepressants, to mitigate early anxiety exacerbation. Long-term data, however, are sparse, and most combination studies focus on the acute phase.

Concerns with Long-Term Use:

1. Tolerance and Dependence:
   • Long-term BZD use is associated with tolerance (requiring higher doses for the same effect) and dependence, with withdrawal symptoms often mimicking anxiety.
   • This complicates distinguishing between anxiety relapse and withdrawal during tapering in long-term trials.
2. Cognitive Effects:
   • Chronic BZD use is linked to potential cognitive impairment, particularly in attention and memory, which may persist even after discontinuation.
3. Risk of Misuse:
   • Prolonged use carries a risk of misuse, particularly in populations with comorbid substance use disorders.
4. Lack of Evidence-Based Guidelines:
   • While short-term efficacy is well-documented, there is insufficient RCT evidence to strongly support long-term BZD use as a monotherapy for anxiety disorders.

Clinical Implications:

• Indications for Long-Term Use:
  • Long-term use may be justified in select patients, such as those who fail other treatments, have contraindications to antidepressants, or require intermittent use for episodic anxiety (e.g., situational SAD).
• Guidelines and Best Practices:
  • Professional guidelines typically recommend using BZDs as a short-term bridge or for situational anxietywhile prioritizing SSRIs, SNRIs, or CBT for long-term management.
  • If BZDs are used long-term, clinicians should aim for the lowest effective dose, regularly reassess the risk-benefit ratio, and educate patients about dependence.